To date, the only FDA-approved drug that targets TF is an antibody–drug conjugate (ADC) used for the treatment of recurrent or metastatic cervical cancer named tisotumab vedotin-tftv (TisVed) [10,11]. Here, TF is linked to cervical cancer.